Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-12 Statins
| Atorvastatin |
|
First Choice
|
Tablets 10mg, 20mg, 40mg, 80mg
|
 MHRA: Statins: interactions, and updated advice for atorvastatin |
|
Chewable tablets 10mg, 20mg (Restricted for use in patients for whom the standard tablets are not suitable who would otherwise require a liquid)| Pravastatin |
|
Formulary
|
Tablets 10mg, 20mg, 40mg Restricted to use in patients who cannot tolerate other statins. |
|
Links
EMA recommends withdrawal of Tredapative
Enoxaparin for Treatment of Venous Thromboembolism **FOR USE IN THE BLACKPOOL REGION ONLY** - Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
- Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
- LSC Hypertension in Adults: Diagnosis and Management
- LSC Patient Pathway for Commencing Inclisiran
- LSC Patient Pathway for Commencing Inclisiran
- LSC Patient Pathway for Commencing Inclisiran
- LSC Statin Intolerance Pathway
- LSC Statin Intolerance Pathway
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Colesevelam for Cardiovascular Disease (CVD) prevention NMR
- LSCMMG: Evolocumab NMR
- LSCMMG: Fenofibrate NMR
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- MHRA: Fibrates: first-line treatment not recommended
- MHRA: Fibrates: first-line treatment not recommended
- MHRA: Statins: interactions, and updated advice for atorvastatin
- MHRA: Statins: interactions, and updated advice for atorvastatin
- MHRA: Statins: risk of hyperglycaemia and diabetes
- MHRA: Statins: very infrequent reports of myasthenia gravis
- NHSE: Clinical Commissioning Policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults) [1679]
- NHSE: Funding and supply of inclisiran (Leqvio®)
- NHSE: Summary of national guidance for lipid management
- NICE HST13: Volanesorsen for treating familial chylomicronaemia syndrome
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG185: Acute Coronary Syndromes
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG196: Atrial fibrillation: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification
- NICE NG242: Diabetic retinopathy: management and monitoring
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA1002: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
- NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
- NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
- NICE: schizophrenia - omega-3 fatty acid medicines
- NICE: schizophrenia - omega-3 fatty acid medicines
- Policy and procedure for prophylaxis against, and treatment of, VTE in adult patients **FOR USE IN THE CENTRAL LANCS REGION ONLY**
- Prevention of VTE in Medical Surgical Patients (16 years +) and those requiring lower limb plaster casts/immobilisations **FOR USE IN THE BLACKPOOL REGION ONLY**
- Renal: Enhanced Supportive Kidney Care Guideline
- UKMI Q & A: Review of evidence for dyslexia